Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund grew its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 32,830 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,727 shares during the period. Illinois Municipal Retirement Fund’s holdings in Supernus Pharmaceuticals were worth $950,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company’s stock worth $167,410,000 after acquiring an additional 28,711 shares in the last quarter. Armistice Capital LLC increased its stake in Supernus Pharmaceuticals by 1.1% in the third quarter. Armistice Capital LLC now owns 5,092,000 shares of the specialty pharmaceutical company’s stock valued at $140,386,000 after purchasing an additional 56,000 shares during the period. Loomis Sayles & Co. L P increased its stake in Supernus Pharmaceuticals by 8.6% in the third quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company’s stock valued at $47,703,000 after purchasing an additional 136,964 shares during the period. Polar Capital Holdings Plc increased its stake in Supernus Pharmaceuticals by 10.0% in the third quarter. Polar Capital Holdings Plc now owns 1,654,470 shares of the specialty pharmaceutical company’s stock valued at $45,614,000 after purchasing an additional 150,000 shares during the period. Finally, Congress Asset Management Co. MA boosted its holdings in shares of Supernus Pharmaceuticals by 19.1% in the third quarter. Congress Asset Management Co. MA now owns 917,164 shares of the specialty pharmaceutical company’s stock valued at $25,286,000 after acquiring an additional 147,105 shares in the last quarter.

Supernus Pharmaceuticals Stock Up 2.6 %

Shares of Supernus Pharmaceuticals stock opened at $30.07 on Monday. The company has a 50-day moving average of $31.51 and a two-hundred day moving average of $28.63. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $38.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a net margin of 0.22% and a return on equity of 0.14%. The company had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. During the same quarter in the previous year, the business posted $0.43 earnings per share. Supernus Pharmaceuticals’s revenue was down 1.8% on a year-over-year basis. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 3,884 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total transaction of $128,133.16. Following the completion of the transaction, the vice president now directly owns 8,570 shares in the company, valued at approximately $282,724.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Padmanabh P. Bhatt sold 12,364 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total value of $436,572.84. Following the transaction, the vice president now directly owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the completion of the transaction, the vice president now owns 8,570 shares in the company, valued at $282,724.30. The disclosure for this sale can be found here. Insiders sold 35,739 shares of company stock worth $1,227,433 in the last ninety days. Insiders own 8.76% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler decreased their price target on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.